Advertisement

Topics

Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial

04:04 EDT 17 Aug 2017 | PharmaTimes

Novo Nordisk’s once-weekly diabetes drug semaglutide has beaten Eli Lilly’s once-weekly therapy dulaglutide on reducing blood sugar and weight in patients taking part in a late-stage trial.

Original Article: Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial

NEXT ARTICLE

More From BioPortfolio on "Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...